bf/NASDAQ:RNXT_icon.jpeg

NASDAQ:RNXT

RenovoRx

  • Stock

0.99

+3.14%

−0.25

USD last updated 14/08 01:46:41

Last Close

1.24

14/08 22:29

Market Cap

27.78M

Beta: -

Volume Today

112.61K

Avg: 55.01K

PE Ratio

−1.91

PFCF: −1.75

OverviewFinancialsAPI

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

    Description

    RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is hea...Show More

    Excel Tearsheet

    Earnings

    Earnings per Share (Estimate*)

    -0.4-0.3-0.2-0.12020-03-302021-06-292022-05-162024-03-072024-08-152025-08-13

    Revenue (Estimate*)

    0.000.000.010.010.012020-03-302021-06-292022-05-162024-03-072024-08-152025-08-13

    *Estimate based on analyst consensus